Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT05076721 Completed - Sepsis Clinical Trials

Effectiveness of Simulation Based Training in Implementing One Hour Bundle Sepsis

Start date: August 22, 2020
Phase: N/A
Study type: Interventional

This study aimed to compare simulation training with conventional training (case-based discussion only) to improve team performance in implementing one-hour sepsis bundle in the intensive care unit

NCT ID: NCT05076435 Completed - Sepsis Clinical Trials

Restrictive Fluid Administration vs. Standard of Care in Emergency Department Sepsis Patients

REFACED Sepsis
Start date: November 3, 2021
Phase: Phase 2
Study type: Interventional

This is an investigator-initiated, multicenter, randomized, parallel-group, open-labeled, feasibility trial investigating volumes of fluid within 24 hours in 124 patients with sepsis allocated to two different IV fluid regimens enrolled at three emergency departments in Central Region Denmark. The primary outcome is total intravenous, crystalloid fluid volume within 24 hours and key secondary outcomes include protocol violations, total fluids (intravenous and oral) within 24 hours, SAEs/SUSARs, and inhospital-, 30- and 90-day mortality.

NCT ID: NCT05072145 Completed - Sepsis Clinical Trials

Evaluating Tele-Emergency Care in Costs and Outcomes for Rural Sepsis Patients

TELE-Cost
Start date: April 1, 2022
Phase:
Study type: Observational

Sepsis is a life-threatening emergency for which provider-to-provider telemedicine has been used to improve quality of care. The objective of this study is to measure the impact of rural tele-emergency consultation on long-term health care costs and outcomes through decreasing organ failure, hospital length-of-stay, and readmissions.

NCT ID: NCT05060679 Completed - Sepsis Clinical Trials

Presepsin:Gelsolin Ratio in Sepsis-related Organ Dysfunction

Start date: January 1, 2018
Phase:
Study type: Observational

In the present study, 126 patients were enrolled (23 control, 38 non-septic and 65 septic patients). Blood samples were collected from septic patients at the intensive care unit (ICU) at three time points (T1-3): T1: within 12h after admission; T2: second day morning; T3: third day morning. Sampling points for non-septic ICU patients were T1 and T3. Exclusion criteria were patients under 18 years of age, unobtainable consent, end-stage renal disease requiring chronic dialysis or kidney transplantation and patients with malignancies needing palliative care. Not more than one sample (venous blood) was collected from control patients. Plasma presepsin levels were determined by an automated chemiluminescence-based Point of Care instrument while serum gelsolin levels were measured using an automated immune turbidimetric assay. Plasma presepsin concentrations were expressed as pg/mL, while serum gelsolin levels were expressed as mg/L. Data were compared with laboratory and clinical parameters. Patients were categorized by the Sepsis-3 definitions and 10-day mortality data were investigated. Presepsin:gelsolin ratio was evaluated in major sepsis-related organ dysfunctions including hemodynamic disturbances, respiratory insufficiency and acute kidney injury (AKI).

NCT ID: NCT05059808 Completed - Sepsis Clinical Trials

European Sepsis Care Survey

Start date: August 1, 2021
Phase:
Study type: Observational

The objective of this survey is to investigate the current state of sepsis care around Europe. The study is aiming at hospital structure, emergency departments, wards, intensive care units and clinical diagnostic and microbiological service.

NCT ID: NCT05022043 Completed - Neonatal Sepsis Clinical Trials

Serum Presepsin as Early Predictor for Neonatal Early-onset Sepsis

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

124 neonates aged ≤7 days with suspected EOS were clinically evaluated using SNAP-II and gave blood samples for BC, total leucocytic count (TLC), lymphocytic and neutrophil count, and ELISA estimation of serum levels of PSP, procalcitonin (PCT), and tumor necrosis factor-α (TNF-α). Enrolled neonates were categorized as Confirmed EOS: neonates with evident clinical sepsis manifestations and positive BC, Suspected EOS: neonates with evident clinical sepsis manifestations but had negative BC and No EOS included neonates free of evident clinical sepsis manifestations, had negative BC and showed no deterioration till 72-hr after admission.

NCT ID: NCT05002413 Completed - Bacteremia Sepsis Clinical Trials

Nanomotion-based Resistell AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia and/or Sepsis

NANO-RAST
Start date: June 18, 2021
Phase:
Study type: Observational

Blood culture samples from bacteremia patients positive for Gram-negative bacteria will be tested for antibacterial susceptibility using Resistell Phenotech device. The results will be compared with current AST gold standard tests to calculate sensitivity, specificity, and accuracy of Resistell Phenotech device.

NCT ID: NCT04991376 Completed - Sepsis Clinical Trials

Specific miRNAs in Sepsis and Nephrotoxic Antibiotic Treatment

Start date: May 2, 2019
Phase:
Study type: Observational

Critically ill patients are prone to develop acute kidney injury due to sepsis itself and by administration of potentially nephrotoxic antibiotic treatment (vancomycin or gentamicin). Blood-specific miRNA levels associated with renal tubular damage change in patients treated with vancomycin or gentamicin compared to septic patients treated with other antimicrobials.

NCT ID: NCT04989569 Completed - Sepsis Clinical Trials

Serial Body Composition Change for Risk Prediction and Nutritional Guide in Treating Patients With Sepsis

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

To explore whether serial changes of data in body composition of patients with sepsis can help clinician to monitor prognosis.

NCT ID: NCT04968262 Completed - Sepsis Clinical Trials

Urinary Actin, as a Potential Marker of Sepsis-related Acute Kidney Injury

Start date: January 1, 2016
Phase:
Study type: Observational

In our study, 17 septic, 43 sepsis-related acute kidney injury and 24 control patients were enrolled. Blood and urine samples were collected at the intensive care unit from acutely diagnosed septic and sepsis-related acute kidney injury patients at three time points (T1-3): T1: within 24 hours after admission; T2: second day morning; T3: third day morning of follow-up. Patients with malignancies needing palliative care, end-stage renal disease or kidney transplantation were excluded. Not more than one sample (venous blood, midstream spot urine) was collected from control patients. Serum and urinary actin levels were determined by quantitative Western blot. Urinary actin concentrations were expressed as µg/L, while serum actin levels were expressed as mg/L. Data were compared with laboratory and clinical parameters. Patients were categorized by the Sepsis-3 definitions and 30-day mortality data were investigated.